Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Zentalis Pharmaceuticals Inc’s stock clocked out at $1.36, down -1.45% from its previous closing price of $1.38. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 0.55 million shares were traded. ZNTL stock price reached its highest trading level at $1.38 during the session, while it also had its lowest trading level at $1.32.
Ratios:
To gain a deeper understanding of ZNTL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.76 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Matrix Capital Management Comp sold 7,500,000 shares for $1.33 per share. The transaction valued at 9,975,000 led to the insider holds 6,459,973 shares of the business.
Myers Scott Dunseth bought 21,000 shares of ZNTL for $29,373 on Apr 30 ’25. The Director now owns 281,192 shares after completing the transaction at $1.40 per share. On Feb 06 ’25, another insider, Bruns Ingmar, who serves as the Chief Medical Officer of the company, bought 20,000 shares for $2.28 each. As a result, the insider paid 45,656 and bolstered with 36,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 98261056 and an Enterprise Value of -141978944. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.66 while its Price-to-Book (P/B) ratio in mrq is 0.39. Its current Enterprise Value per Revenue stands at -5.285 whereas that against EBITDA is 0.936.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.75, which has changed by -0.53424656 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $3.33, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -4.59%, while the 200-Day Moving Average is calculated to be -6.32%.
Shares Statistics:
It appears that ZNTL traded 720.00K shares on average per day over the past three months and 1055440 shares per day over the past ten days. A total of 72.25M shares are outstanding, with a floating share count of 59.50M. Insiders hold about 17.65% of the company’s shares, while institutions hold 65.06% stake in the company. Shares short for ZNTL as of 1765756800 were 5496827 with a Short Ratio of 7.63, compared to 1763078400 on 5084883. Therefore, it implies a Short% of Shares Outstanding of 5496827 and a Short% of Float of 9.49.
Earnings Estimates
The dynamic stock of Zentalis Pharmaceuticals Inc (ZNTL) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.38 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.37 and -$1.95 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.6, with 7.0 analysts recommending between -$1.05 and -$2.27.
